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Diabetes is associated with increased risk of cardiovascular disease, coronary 
heart disease, stroke, acute myocardial infarction, blindness, and renal failure. 
Strategies to reduce their occurrence are an essential focus of patient care. 
More than one pathogenic process is involved, and genetics influence the risk. 
Hyperglycemia is a factor in the development of microvascular and possibly 
macrovascular complications. Two possible mechanisms of glucose damage 
are glycation of proteins and the polyol pathway. Research led to the 
identification of drugs that block parts of the pathways. In clinical trials, 
intensive control of blood glucose concentrations decreased the risk of 
microvascular complications. Adverse effects associated with intensive 
therapy, however, include hypoglycemia and weight gain. 
(Pharmacotherapy 1998; 18( 5):96 1-972) 
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Diabetes mellitus is associated with 2-3 times 
the risk of cardiovascular disease, coronary heart 
disease and stroke' and is implicated in 25% of 
acute myocardial infarctiom2 It is the leading 
cause of blindness in the United States and of 
renal failure.2, Individuals with diabetes are 2.5 
times more likely to be hospitalized than those 
without the disease.2 Overall, it is estimated that 
the cost of diabetes in the United States is $92 
billion/year.2 
Epidemiologic and clinical data showed an 
association between hyperglycemia and the 
complications of diabetes.3d Diagnostic criteria 
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for diabetes are based on  the relationship 
between hyperglycemia and retinopathy, 
nephropathy, and macrovascular d i~ease .~  The 
degree of glycemic control contributes to the risk 
of nephropathy and retinopathy in patients with 
type 1 disease.'j Approximately 25% of people 
with diabetes never develop chronic complications 
regardless of glycemic control,  whereas 
approximately 5% develop severe complications 
within a few years of diagnosis.' Hypertension 
and  hyperlipidemia occur frequently and  
contribute to vascular disease.' 
Mechanisms of Damage from Hyperglycemia 
Identifying the mechanisms by which glucose 
causes damage may be helpful in developing 
ways to prevent complications. It is likely that 
more than one pathogenic process is involved, 
and the critical process may vary with the 
compli~ation.~ Furthermore, there is an apparent 
genetic influence on the risk of complications. 
Many physiologic abnormalities have been 
associated with hyperglycemia. Acute effects 
include elevated protein kinase C activity, 
hyperlipidemia, alterations in renal hemodynamics, 
abnormalities in prostacyclin activity, rheologic 
abnormalities, and hypersensitivity of platelets.l~12 
Many of these disorders are reversible with 
correction of hyperglycemia.l0, l1 Therefor;, it is 
not known why they may progress, or even 
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appear for the first time, after glucose is 
corrected. l3 Two possible mechanisms of long- 
term glucose toxicity are glycation of proteins 
and the polyol pathway. Research into each 
mechanism has been the impetus for the 
development of new drugs. 
Glycation of Proteins 
Glucose and proteins undergo a complex series 
of reactions that ultimately results in irreversible 
alterations in tissue structure and interference 
with normal protein function. For this reason, 
glycation of proteins was proposed as an  
explanation for so-called hyperglycemic memory, 
or continued destruction of tissues after 
restoration of glycemic contr01.l~ Some 
individuals may produce enzymes capable of 
metabolizing precursors of glycated proteins to 
result in less harmful m01ecules.l~ This is also a 
possible explanation for genetic differences in 
risk of complications; that is, those who can 
efficiently clear glycated proteins may be at 
decreased risk compared with those who cannot. 
Decreased renal clearance of glycated proteins 
may be involved in  acceleration of some 
complications in patients with declining renal 
function. The glycation sequence, which is not 
completely described, begins when sugar 
molecules undergo nucleophilic addition 
reactions with free amino groups on proteins to 
form molecules called Schiff bases (Figure l).15 
Because the reaction is nonenzymatic and  
reversible, these early glycated proteins are 
formed in proportion to the surrounding glucose 
concentration. The reaction is rapid and reaches 
equilibrium within hours. l5 These compounds 
are unstable and undergo further rearrangement 
to the Amadori product (1-amino-l-deoxy-D- 
ketose).13 
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Figure 1. Proposed steps in the formation of glycated end 
products. 
Reactions involved in formation of Amadori 
compounds are also reversible, although slower, 
reaching equilibrium in several weeks. The 
concentration of Amadori compounds is related 
to mean blood glucose concentration over the 
previous weeks. Amadori products eventually 
degrade, resulting in carbonyl compounds that 
are highly reactive with free amino groups. 
These ultimately form complexes known as 
intermediate and advanced glycated end products 
(AGEs) or advanced glycated proteins (AGPs). 
Once AGEs have formed, the process is irreversible. 
Therefore, the concentration of AGEs is a reflection 
of overall glucose concentration throughout life. 
These reactions occur in everyone to an extent 
determined by blood glucose concentrations. 
Normally, the process may be involved in tissue 
remodeling and removal of aging macrom~lecules 
from the circulation.16 This may explain why 
some chronic pomplications of diabetes resemble 
acceleration of the aging process. 
Several mechanisms have been identified by 
which AGEs interfere with normal tissue 
function. Some abnormalities in diabetes may 
result from AGEs attaching to proteins of the 
extracellular matrix. The extracellular matrix is 
widened in  all types of vessels in  diabetes, 
including basement membranes of the retinal and 
vasa nervorum, and mesangial matrix of the 
glomerulu~.~’  Alterations in the structure of 
basement membrane may result i n  part by 
binding of AGEs to type IV collagen and laminin, 
interfering with their ability to self-assemble and 
associate with other basement membrane 
macromolecules. l9 Other consequences of 
glycation cause the basement membrane to be 
less susceptible to normal proteolytic degradation 
and inactivation of nitric 
Further problems are caused by AGEs on 
collagen in  vessel walls that have increased 
binding to low-density lipoprotein (LDL) and 
immunoglobulin G (IgG).23v 24 Bound LDL and 
IgG are likely to react further with glucose and 
glycated proteins to form additional AGEs. 
Thickening of vessel walls is in  part a direct 
consequence of the accumulation of these bound 
proteins.17 In addition, macrophages and 
monocytes have receptors that interact with 
AGEs, triggering release of cytokines such as 
tumor necrosis factor and interleukin-1, and 
ultimately the release of growth factors.16 These 
processes are involved in formation of athero- 
sclerotic plaques.25 Release of these factors and 
diminished activity of nitric oxide may also 
contribute to the cellular proliferation associated 
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with retinopathy, nephropathy, and ne~ropathy.'~, 26 
Binding of AGEs to receptors on endothelial 
cells induces changes in coagulation pathways 
that promote thrombosis and stimulates 
production of endothelial-1, which has vaso- 
constrictive activity. A separate mechanism of 
AGE-induced damage involves glycation of DNA 
and R N A ,  which results i n  mutations and 
abnormal expression of genes in experimental 
models. 27-29 
Several agents were investigated for activity in 
inhibiting AGE development. Pimagedine is an 
investigational drug that interferes with 
formation of AGEs and may have other actions as 
well.30 Its efficacy was shown in studies in 
animal models of retinopathy and nephropathy. 
In an  open label study in  18 humans with 
diabetes, hemoglobin AGE concentrations 
decreased significantly during 1 month of 
treatment with  imaged dine.^^ A large randomized, 
double-blind study of the drug is under way.14 If 
pimagedine proves to be reasonably safe and 
effective, it may play a role as an adjuvant to 
intensive efforts to control blood glucose. Other 
compounds, such as thiamine pyrophosphate and 
pyridoxamine, also block AGE formation and are 
under investigation for this i n d i ~ a t i o n . ~ ~  
Antioxidants reduce AGE formation,33 and 
vitamin E has variable efficacy in  reducing 
protein g lyca t i~n .~~?  35 
Polyol Pathway and Myoinositol 
In  the polyol pathway, aldose reductase 
catalyzes the reduction of glucose to sorbitol, 
which is then oxidized to fructose by sorbitol 
dehydrogenase (Figure 2). This is a minor 
pathway in individuals with normoglycemia, but 
accounts for significant glucose disposal in the 
presence of hyperglycemia. Specifically, it is 
important in noninsulin-dependent cells that take 
up glucose in proportion to blood concentration. 
Sorbitol does not traverse cell membranes as 
easily as does glucose and accumulates in  
affected cells.36 Some chronic complications of 
diabetes, such as retinopathy, nephropathy, and 
neuropathy, are manifested in tissues that include 
noninsulin-dependent cells.36 For this reason, 
the polyol pathway may contribute to these compli- 
cations, although the mechanism is disputed. 
Effects associated with increased polyol activity 
in  peripheral nerve tissue are depletion of 
myoinositol and decrease in Na', K+-adenosine 
triphosphatase (ATPase) activity.37, 38 Another 
mechanism of damage from sorbitol is through 
glycation of proteins. Sorbitol is more likely to 
exist in the reactive open form of sugars than is 
glucose. Therefore, in cells with high concentrations 
of sorbitol, reactions between sugars and proteins 
are accelerated. l4 In addition, accumulation of 
the reduced form of nicotinamide adenine 
dinucleotide may contribute to complications by 
altering the redox state and allowing a rise in the 
concentration of diacylglycerol (DAG), and 
increased activation of some isoforms of protein 
kinase C (PKC).39 Activation of PKC causes 
effects such as reduced Na', K-ATPase activity 
and changes in vascular c~ntractility.~~! 40 Other 
abnormalities associated with polyol pathway 
activity are diminished nitric oxide synthetase 
and some structural lesions.38, 41 
Aldose reductase inhibitors were developed to 
interfere with accumulation of sorbitol  i n  
noninsulin-dependent cells and, it was hoped, 
with development of complications of diabetes. 
The agents have some beneficial effects i n  
diabetic neuropathies, including restoration of 
myoinositol concentrations.36- 42 Intracellular 
concentrations of myoinositol and nerve 
conduction were improved with administration 
of either myoinositol or  aldose reductase 
inhibitors in animal models.36, 43 A meta-analysis 
of controlled trials with tolrestat found it to be 
effective in slowing loss of nerve function in 
existing peripheral neuropathy.# 
Vitamins E and C also show promise in  
preventing c o m p l i ~ a t i o n s . ~ ~ ~  45 Vitamin E 
produces a decrease in DAG concentrations in 
vascular cells, thereby preventing activation of 
PKC.40 This prevents hyperglycemia-induced 
changes in retinal blood flow in diabetic rats.40 
Ascorbic acid inhibits the reduction in  
myoinositol produced by the polyol pathway.45 
Clinical Trials 
Type 1 Diabetes Mellitus 
Many trials examined the association between 
blood glucose concentrations and the onset or 
progression of chronic complications of diabetes. 
-1 [r( INAD+] 
Figure 2. The polyol pathway. 
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These studies are complicated by a number of 
factors, including the fact that blood glucose 
concentrations are not the only determinants of 
risk. Early clinical trials of glucose control had 
some additional problems, such as small 
numbers of subjects in controlled trials and short 
duration. Until recently, methods of monitoring 
were not available to achieve and document 
significant differences in  metabolic control 
between groups.46 Subjects using urine glucose 
monitoring could not  safely maintain near 
normoglycemia, and investigators using 
occasional blood glucose monitoring had 
difficulty determining overall glucose control.47 
However, in the early 1980s, self-monitoring of 
blood glucose became a~a i l ab le .~~  An additional 
advance was glycated hemoglobin measurement, 
which provides an objective and reproducible 
comparison of integrated differences in glycemic 
control between groups.49 The utility of these 
two monitoring methods made possible well- 
controlled comparisons of intensive and 
conventional therapy6, 46 
An early study of glycemic control and  
complications compared the effects of single 
(SDI) and multiple (MDI) daily injections of 
insulin on the progression of retinopathy in 42 
subjects with early stages of diabetic retinopathy50 
Five of 21 subjects randomized to SDI were 
changed to two or three injectiordday because of 
poor glucose control, and those randomized to 
MDI received one to three injectiodday. During 
the 3-year trial, mean fasting blood glucose 
measurements were not significantly lower in the 
MDI than SDI group, although significance was 
reached during the last year of the study (154 * 
15 vs 195 * 11 mg/dl, pe0.05). Both groups had 
a significant increase in microaneurysms, but the 
yearly increase was smaller in the MDI 
Unfortunately, the large number of subjects 
moving between treatment groups makes the 
data difficult to interpret. 
Retinopathy and neuropathy were studied in 
74 subjects with background retinopathy who 
were randomized to continue their regular 
regimen or start intensive therapy51 Glycated 
hemoglobin was lower in intensively treated 
subjects at 8 and 12  months, but not at 24 
months. Creatinine clearance deteriorated in the 
conventionally treated group and was significantly 
lower than in the intensive group at 2 years (82.9 
* 26.0 and 99.1 * 29.6 mVmin, pe0.05). No 
significant changes in retinopathy were seen in 
either group. Sensory nerve function improved 
in  subjects receiving intensive therapy and 
worsened in those having conventional therapy 
The lack of a dramatic difference in glycemic 
control between groups may have contributed to 
the absence of effects on retinopathy 
The effects of strict metabolic control on 
retinopathy and renal function were investigated 
in a series of studies of continuous subcutaneous 
infusions of insulin (CSII) .52-57 Thirty-four 
patients were randomized to either CSII or 
conventional treatment, which consisted of three 
injectiondday in 13 of 15 patients.52, 53 Glycated 
hemoglobin concentration decreased in both 
groups and was significantly lower in the CSII 
group after 2 months. After 1 year, deterioration 
in retinopathy was more frequent in subjects 
receiving CSII, especially in those with well- 
regulated blood Urinary albumin 
excretion showed a trend to decrease by 6 
months and glomerular filtration rate (GFR) 
decreased signtficantly by 9% (pc0.01) in the 
CSII group, whereas urinary albumin excretion 
increased by 56% (pe0.01) and GFR was unchanged 
in patients who received conventional treatment. 
A second study assessed renal function in 36 
subjects with elevated urinary albumin excretion 
randomly assigned to CSII or conventional 
therapy.55. 56 A lower mean glycated hemoglobin 
in CSII-treated subjects was maintained during 2 
years of study. The fractional clearance of 
albumin increased with conventional treatment 
during the second year and declined in the CSII 
group, and clinical nephropathy developed in five 
patients treated conventionally compared with no 
CSII Investigators continued to follow 
69 of 70 subjects from both studies. Subjects 
were allowed to change treatment group after 2 
years, and 18 did so. After 3 years, the groups 
did not differ significantly with respect to 
glycated hemoglobin concentrations and vision 
acuity. Direct associations were found between 
mean glycated hemoglobin and urinary albumin 
excretion (pe0.01) and change in  urinary 
albumin excretion (pe0.01). Changes in study 
design cast doubt on the findings. However, 
these studies showed that although tight glucose 
control can cause an  initial worsening of 
retinopathy, this effect may be transient. 
In 68 subjects, diabetic retinopathy advanced 
more rapidly in  those receiving CSII than in 
those treated c~nventionally.~~ At follow-up in 
64 patients after 2 years, 11 receiving CSII and 10 
receiving conventional treatment had switched 
regimens. The CSII group continued to have 
superior glycemic control based on glycated 
hemoglobin concentrations; however, the degree 
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of retinopathy in  the two groups was not 
significantly different.*' Despite problems with 
patients crossing over to the other regimen, these 
studies support  the concept that the initial 
worsening in established retinopathy seen with 
strict control may not be evident in the long term. 
In 45 patients, CSII was compared with MDI ( 5  
or 6 injectiondday) or conventional treatment (2 
injectiondday) .60-62 After 2 years, glycated 
hemoglobin concentrations were lower in  
subjects treated with CSII and MDI compared 
with conventionally treated subjects (p<O.Ol). 
Compared with baseline, conventionally treated 
patients had an increased frequency of micro- 
aneurysms and retinal hemorrhages (pcO.01). In 
addition, they had more microaneurysms and 
hemorrhages than patients given CSII and MDI 
(pc0.05). Mean urinary albumin excretion did 
not change significantly in any group compared 
with baseline. Despite transient worsening of 
retinopathy, intensive therapy appeared to be 
beneficial in delaying progression of complications. 
Another trial comparing CSII and conventional 
therapy in 24 subjects with no or minor back- 
ground retinopathy and no albuminuria reported 
no difference between groups with respect to 
progression of retinopathy after 6 months or 
urinary albumin excretion after 1 year.63 These 
data suggest that  in patients with minimal 
retinopathy, intensive therapy may not involve a 
risk of initial deterioration. 
The effects of MDI and conventional treatment 
on the development of microvascular complications 
were compared in 96 patients with nonproliferative 
retinopathyM3 65 Glycated hemoglobin concentrations 
decreased in both groups (MDI 9.5 * 0.2% to 7.2 
* 0.1%, p<O.OOl; conventional treatment 9.4 * 
0.2 to 8.7 * 0.1%, peO.001). Retinopathy 
progressed in both groups, but after 5 and 7 years 
it was worse in subjects given conventional 
treatment (pc0.05). In addition, urinary albumin 
excretion was higher and neuropathy worse in 
these patients (pc0.05). 
The Diabetes Control and Complications Trial 
(DCCT) studied the effect of intensive therapy in 
1441 subjects6 Inclusion of patients relatively 
soon after diagnosis of diabetes and with no or 
early complications allowed investigation of the 
influence of intensive therapy on both primary 
prevention and early intervention. Inclusion 
criteria were type 1 diabetes, age 13-39 years, 
and no evidence of hypertension, hypercholes- 
terolemia, severe diabetic complications, or other 
medical conditions. Individuals with a 1- to 5- 
year history of type 1 diabetes mellitus, no signs 
of retinopathy, and urinary albumin excretion 
less than 40 mg/24 hours were included in the 
primary prevention cohort, and those with a 
history of type 1 diabetes for 1-15 years, mild to 
moderate nonproliferative retinopathy, and 
urinary albumin excretion less than 200 mg/24 
hours were the secondary intervention cohort. 
Subjects were randomized to either intensive or 
conventional therapy. Those given conventional 
therapy had one or two insulin injectiondday. 
Those treated with intensive therapy had three or 
more injections of insulidday or an insulin 
pump, and monitored their own blood glucose at 
least 4 times/day with goals of normal blood 
glucose and glycated hemoglobin concentrations. 
Re tin o p a thy, n eu r o p a thy, n e p h r o p a thy, and 
vascular disease were assessed. 
The mean glycated hemoglobin value was 
significantly different between intensive and 
conventional treatment groups in both primary 
and secondary intervention cohorts (peO.001). 
The frequency of retinopathy was similar in the 
intensive and conventional control groups for 
the first 3 years, but in the long term, intensive 
therapy reduced the risk of retinopathy in both 
primary and secondary intervention cohorts. A 
linear association existed between glycated 
hemoglobin concentrations and retinopathy in 
both cohorts. Furthermore, the frequencies of 
microalbuminuria and neuropathy were reduced 
in both cohorts. N o  differences were found 
between groups in  the frequency of any 
individual vascular event. However, the trend 
was toward a decrease in combined vascular 
events with intensive treatment, and intensive 
therapy decreased the development of hyper- 
cholesterolemia. Mortality rates were not  
significantly different between treatment groups 
and were lower than expected from population- 
based mortality studies. However, the frequency 
of severe hypoglycemia was 3 times higher in 
intensively treated than in conventionally treated 
patients (p<O.OOl). Patients who monitored 
their own blood glucose gained more weight 
than their counterparts receiving conventional 
therapy. 
The DCCT established that the risk of develop- 
ment and progression of microvascular complications 
of diabetes is related to the degree of metabolic 
control. Intensification of glucose control is 
associated with deterioration of pre-existent 
retinopathy, but long-term improvement delays 
progression of retinopathy. The implications for 
macrovascular disease are not yet known. Table 
1 summarizes these studies. 
966 PHARMACOTHERAPY Volume 18, Number 5 ,  1998 
Table 1. Controlled Clinical Trials of the Effect of Glycemic Control on Chronic Complications in Type 1 Diabetes 
Outcomes 
Study No. of Duration Glycated 
Population Pts Treatment (yrs) Nephropathy Retinopathy Hemoglobin (%) 
MDI vs SDI 3 42 NA Age < 60 yrs, 
oncdday insulin, 
early retinopathy 
Age < 60 yrs, 
no renal impairment, 
significant CV history, 
or proliferative 
retinopathy 
Age 18-51 yrs, 
diabetes < 35 yrs, 
background 
retinopathy, normal 
serum creatinine 
Age 18-51, diabetes 
< 35 yrs,background 
retinopathy, normal 
serum creatinine 
Age 18-50 yrs, 
diabetes 5-26 yrs, 
elevated UAE, no 
active proliferative 
retinopa thy 
Age 18-50 yrs, 
diabetes 5-26 yrs, 
elevated UAE, no 
active proliferative 
retinopathyg 
Age 18-51, diabetes 
< 35 yrs, normal 
serum creatinine: 
1 group with 
background 
retinopathy, 1 
with elevated UAE 
Age 14-60 yrs, 
weight < 130% IBW, 
diabetes < 30 yrs, 
insulin dosage 15-120 
U/day for < 2 yrs, 
mild nonproliferative 
retinopathy 
Age 18-41 yrs, 
diabetes 5-20 yrs, 
no or minor 
background 
retinopathy 
74 
30 
30 
36 
36 
69' 
68 
24 
CT' vs ITd 
CT' vs CSII 
CT' vs CSlI 
CT'vs CSII 
CT'vs CSII 
CT' vs CSII 
CTJ vs CSII 
CTk vs CSII 
NA 
NA 
NA 
No differences 
between groups 
with respect to 
UAE or GFR. 
Diabetic nephropathy 
developed more 
often in CT vs CSII, 
5 vs gb; UAE 
increased in CT vs 
CSII, +7 vs -9b. 
Greater increase 
microaneurysms 
SDI vs MDI, 7.2 i 
1.9 vs 1.8 * 0.7." 
No significant , 
differences between 
groups. 
Improved retinal 
function in CSII and 
worse in CT; worse 
retinal morphology 
in CSII but not CT. 
function in CT,b 
CSII unchanged, 
improved retinal 
morphology in CSII 
vs CT? 
Worse retinal 
No significant 
differences reported. 
No significant 
differences reported. 
5 or 8 No patients developed No difference in 
nephropathy, no progression to 
differences in UAE; proliferative 
independent retinopathy or in 
variables associated visual acuity. 
with final UAE: 
HbAI,," and initial 
UAE.~  
2 No differences or After 1 yr, more 
changes in patients deterioration in 
with normal baseline mean retinopathy 
UAE; for initial level CSII vs CT"; 
elevated UAE, CSII after 2 yrs CT 
produced decline worsened and CSII 
from baseline but improved.h 
CT did not. 
1 No changes in UAE No differences 
in either group, between groups 
decreased GFR CSII, 
130 i 18-116 * 15 
mVmid1.73 m2: retinopathy. 
but not CT. 
with respect to 
progression of 
NA 
IT lower than CT 
after 4 mo, 
significant at 12 
mo, 10.5 f 1.4 
vs 11.4 * 1.5." 
Decreased in 
both groups but 
significantly 
lower in CSIl 
group. 1 
lower in CSII vs 
CT throughout 
study.a 
Mean values 
Decreased in IT 
vs baseline, 9.5 to 
7.3"; unchanged in 
CT. 9.3 to 9.2. 
Decreased in 
CSII vs baseline, 
9.5 to 7.2.h 
unchanged in CT, 
9.3 to 8.6. 
Greater decrease 
in CSII vs CT for 
both subgroups, 
2.0 i 0.6 vs 0.7 i 
1.2 and 1.8 * 1.2 
vs 0.4 * 1.3." 
Mean levels lower 
in CSII vs CT 
throughout yr 1, 
8.1 It 0.2 vs 
10.0 i 0.3h and 
yr 2,g.o vs 
10.8." 
Final CSII level 
decreased from 
baseline, 8.9 * 2 
to 7.0 i 1.5"; un- 
changed in CT, 9.0 
* 1.9 to 9.1 f 2. 
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Table 1. (continued) 
Glucose 
Concentration (mg/dl) Hypoglycemia Other 
Mean of every third NA NA5' 
Outcomes 
mo fasting glucose 
concentration higher 
SDI vs MDI (154 * 15 
vs 195 * 11): 
NA N o  differences Mean weight 
between groups; unchanged 
1 severe episode both groups; 
in each group. nerve function 
improved in IT, 
worsened CT.b,51 
Mean concentrations N o  differences NA52.53 
lower CSII vs CT, 
112 (range 72-140) vs 
176 (range 122-2S4).a 
between groups; 
6 severe episodes 
in CSII vs 3 in CT. 
Mean concentrations N o  differences NA5 
lower in CSII vs CT 
throughout study." blood glucose 
in frequency of 
concentrations 
< 45; frequency 
of severe episodes 
not reported. 
severe episodes 
CSII vs CT, 3 vs 4. 
Mean of l x  measure- N o  differences in NA55 
ment at end of study 
lower in IT vs CT, 
126 * 18.184 * 36.b 
Median concentration 5 severe episodes NA56 
lower in CSII vs CT, 
119 (range 92-162) 
vs 211 (range 
171-311).h 
both CSII and CT. 
NA N o  significant Systolic blood 
differences pressure 
reported. increased in 
CTb but not 
cs11.57 
Mean plasma N o  differences in NA5'> 59 
concentration during severe episodes 
24-hr profile lower 
in CSII vs CT, 116.9 * 
5.8 vs 175 * 8.€Lh 
CSII vs CT, 9 vs 4. 
Mean daily NA 
concentrations lower 
CSII vs CT, 126 * 25 
vs 166 f 32." 
NA6' 
Type 2 Diabetes Mellitus 
No study of glycemic control in type 2 diabetes 
mellitus was as well-controlled as the DCCT. 
However, several trials showed a relationship between 
glycemia and complications in these patients. 
The University Group Diabetes Program was 
an early attempt to study the effects of various 
treatment options in type 2 disease.66 This was a 
randomized, prospective comparison of cardio- 
vascular and microvascular outcomes achieved 
with five treatment regimens in 1027 patients: 
diet alone, diet plus fixed-dose insulin, diet plus 
variable-dose insulin, diet plus tolbutamide, and 
diet plus phenformin. The fixed-dose regimen 
was no more than 20 U intermediate-acting 
insulin every morning. The variable dose was 
adjusted with the goal of periodic fasting glucose 
concentrations below 130 mg/dl. The study was 
begun in 1961, before evidence of contributing 
risk factors to cardiovascular disease and avail- 
ability of glycated hemoglobin measurements or 
self-monitoring of blood glucose; the phenformin 
group was added later. The tolbutamide and 
phenformin arms were stopped early because 
these patients had an increase in overall and 
cardiovascular mortality. However, the other 
arms continued for 6 years. Improved glucose 
control was not  associated with insulin,  
phenformin, or tolbutamide over the 11 years of 
follow-up. Phenformin and tolbutamide, but not 
insulin, were associated with increased cardio- 
vascular deaths. The results remain controversial 
and have been subjected to several post hoc 
analyses.6749 It is still not known whether choice 
of agent affects the risk of complications 
independent of glycemic control. 
In a prospective study, 1054 elderly (age 65-74 
yrs at baseline) patients were assessed for weight, 
height, blood pressure, evaluation of coronary 
heart disease, glucose tolerance, and glycated 
hemoglobin at baseline and after 2.7-5.2 years.4 
At baseline, 17.9% of men and 19.0% of women 
had impaired glucose tolerance, 7.0% and 7.1% 
had newly diagnosed type 2 diabetes mellitus, 
and 8.7% and 11.6% had previously diagnosed 
type 2 diabetes. In subjects with diabetes, both 
glycated hemoglobin and duration of disease 
were strongly correlated with risk of myocardial 
infarction and other vascular events. Elevated 
glycated hemoglobin was a stronger predictor 
than duration of disease (short duration and 
glycated hemoglobin 2 7.0% were worse than 
long duration and glycated hemoglobin <: 7.0%). 
Other factors, such as current smoking, systolic 
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Table 1. Controlled Clinical Trials of the Effect of Glvcemic Control on Chronic Comdications in T m e  1 Diabetes (cont.) 
Outcomes 
Study No. of Duration Glycated 
Population Pts Treatment (yrs) Nephropathy Retinopathy Hemoglobin (%) 
Age 18-45 yrs, 45 CSII vs MDI' 1, 2 No significant changes Worsening 
iiabetes 7-30 yrs, vs CT" 
no nephropathy, 
hypertension, or 
proliferative 
re tinopathy 
Nonproliferative 95 MDI"vs CT' 
retinopathy, normal 
serum creatinine, 
unsatisfactory 
glycemic control 
Age 13-39 yrs, no 1441 CT'vs IT" 
or early microvascular 
complications, no 
hypertension or 
hypercholes terolemia 
or differences - 
between groups in 
UAE. 
7.5 Fewer patients 
developed 
nephropathy MDI 
vs CT, 1 vs 9.b 
6.5 Decreased risk 
microalbuminuria 
in IT vs CT 
both cohorts, 
primary 34%; 
secondaty 43%." 
retinoparhy in CSII 
at 3 and 6 mo 
but not 1 or 2 yrs; 
MDI had no 
changes throughout 
study; CT worse'at 
1 and 2 yrs.' 
Fewer patients 
developed serious 
retinopathy in MDI 
vs CT, 27% vs 
52%.d 
IT vs CT decreased 
risk of developing 
(76%)' or 
progressing (54%) ." 
Greater decrease 
from baseline in 
CSII vs MDI and 
CT, 10.1 i 0.4 to 
8.7 i 0.3,9.4 i 
0.4 to 9.1 i 0.4, 
9.5 i 0.4 to 10.2 
i 0.5." 
Mean level lower 
in MDI vs CT, 
7.1 i 0.7 vs 8.5 
i 0.7." 
IT lower than CTh 
throughout study. 
MDI = multiple daily injections of insulin; SDI = single daily injection of insulin; CV = cardiovascular disease; CT = conventional therapy; IT = 
intensive therapy; CSII = continuous subcutaneous infusion of insulin; UAE = urinary albumin excretion; GFR = glomerular filtration rate; 
HbAI, = glycated hemoglobin; IBW = ideal body weight; NCV = nerve conduction velocity; NA = not applicable. 
bp<0.05. 
'Conventional treatment consisted of therapy used before the study; 63% were receiving oncefday regmens. 
dIntensive therapy consisted of Ultralente plus short-acting insulin with meals. 
'Conventional treatment consisted of two daily injections for 93.3% patients 
'Conventional therapy consisted of two to three daily injections of short- * intermediate-acting insulin. 
&The same subjects are reported in references 55 and 56. 
'Reference 57 includes subjects who were enrolled but may not have completed studies in references 52,53,55, and 56. 
'Conventional therapy consisted of one to three daily injection of short- i intermediate-acting insulins. 
kConventional therapy consisted of twice daily injections of insulin. 
'Multiple daily injections consisted of short-acting insulin before meals and intermediate-acting insulin at bedtime. 
"Conventional therapy consisted of twicefday injections of short- * intermediate-acting insulin. 
"Multiple daily injections consisted of three or more daily injections in 82%. 
Olntensive therapy consisted of three or more injections of insulin daily with self-monitoring of blood glucose. 
ap<0.01. 
hp<O.OOI. 
blood pressure, and low high-density lipoprotein, 
did not predict coronary heart disease events. 
A prospective study compared an intensive 
insulin regimen with conventional insulin 
therapy in 110 patients who had previously been 
treated with one or  two daily injections of 
insulin.70 Patients with hypertension were 
excluded. The study design resembled that of 
the DCCT, with primary prevention (no  
retinopathy, urinary albumin excretion c 30 
mg/24 hrs) and secondary intervention (simple 
retinopathy, urinary albumin excretion < 300 
mg/24 hrs) cohorts. Those randomized to 
conventional therapy received one or two 
injectiondday of intermediate-acting insulin with 
the goals of preventing symptoms of hypo- 
glycemia and hyperglycemia and maintaining 
fasting blood glucose below 140 mg/dl. The 
intensively treated group received short-acting 
insulin with each meal and intermediate-acting 
insulin at bedtime. A significant improvement in 
glycemic control,  achieved with intensive 
therapy, was associated with a decreased risk of 
microvascular complications. However, exclusion 
of patients with hypertension and the fact that 
few subjects were obese led to questions about 
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Table 1. (continued) 
Outcomes 
Glucose 
Concentration (mg/dl) Hypoglycemia Other 
Greater decrease from Larger increase NA61A3 
baseline in mean from baseline 
glucose concentration in number of 
CSII and MDI vs CT, blood glucose 
160 * 13 to 95.4 * < 45 in CSII than 
5.4, 162 * 14 to MDI, CTb; fewer 
115 * 5.4, 142 * 13 episodes of hypogly- 
to 142 * 9." cemic coma CSII 
than MDI, CT 
(2 vs 14 vs 13Jh 
severe hypo- between groups 
glycemia; in in development 
MDI and CT, of peripheral 
1.1 vs 0.4/ neuropa thy, 
patient-yr. less deterior- 
NA Episodes of No differences 
ation in NCV, 
MDI vs 
CT,~ .  64.65 
Mean blood Severe episodes 41% decrease in 
concentration lower more common total macro- 
in IT vs CT, 155 i 30 in IT vs CT, 
vs 231 * 55.h 62/100 vs IT gained 4.6 
19/100 kg more than 
patient-yrsh CT.6 
vascular events; 
applicability of results to the usual population 
with type 2 diabetes. 
The United Kingdom Prospective Diabetes 
Study (UKPDS) randomized obese patients to 
diet alone or diet plus insulin, chlorpropamide, 
glyburide, or metformin. Nonobese patients had 
the same options with the exception of 
metformin. Long-term outcome data are not yet 
available, although data on glycemic control have 
been published. The results of this study may 
help determine if drug therapy has any affect on 
the development of chronic  complication^.^^^ 72 
Table 2 summarizes studies in type 2 disease. 
A feasibility study was conducted for a large, 
prospective trial of intensive versus conventional 
insulin therapy in patients with poor control 
despite treatment with oral agents or standard 
insulin therapy.73' 74 The study would address 
whether intensive therapy is of benefit in people 
who failed other drug therapies, rather than 
indicating whether intensive therapy from the 
time of diagnosis is beneficial. 
Even if improved glucose control reduces the 
risk of chronic complications in type 2 diabetes, 
drugs may differ in their benefit. Epidemiologic 
data linked hyperinsulinemia in nondiabetics 
with an increased rate of a t h e r o ~ c l e r o s i s . ~ ~  
However, it may be that hyperinsulinemia is a 
marker for, rather than a cause of, cardiovascular 
risks.76 Moreover, clinical trials did not find an 
association between insulin dosages and cardio- 
vascular events. In addition, i t  was theorized 
that sulfonylureas could cause cardiovascular 
toxicity due to closure of ATP-sensitive 
potassium channels; if true, this may vary among 
members of the class.77, 78 Other agents, such as 
thiazolidinediones and  biguanides, have 
potentially beneficial effects on macrovascular 
risks such as decreasing insulin resistance and 
improving the lipid profile.79, 'O The final results 
of the UKPDS should clarify the contribution of 
treatment to risk of complications. 
Special Patient Populations 
The American Diabetes Association (ADA) and 
others identified patients for whom intensive 
therapy may not be Intensive 
therapy should be implemented with great 
caution in patients who experience frequent 
episodes of severe hypoglycemia or have 
hypoglycemic unawarenes~.~ In addition, it is 
contraindicated in  patients with unusual  
potential to suffer harm from hypoglycemia.6, 72 
Those who have had diabetes for 20 or more 
years after adolescence without complications are 
unlikely to develop complications ever and may 
not benefit from intensive therapy'' Because the 
primary benefits in the DCCT were decreased 
occurrence and progression of retinopathy and 
renal disease, having these disorders in advanced 
stages eliminates much of the potential benefit of 
intensive therapy and still carries the risks. 
Therefore, the ADA does not recommend such 
treatment for patients with end-stage renal 
disease or severe retinopathy'l 
The youngest subject enrolled in the DCCT 
was 13 years of age, and the benefits of intensive 
therapy in children have not been well defined.6 
Children may have both a reduced possibility of 
benefiting and an increased risk of harm.', 82, 84 
Epidemiologic data suggest that preadolescent 
children may be protected from the microvascular 
damage of hyperglycemia.82, 85, 86 Hypoglycemia 
in children could impair normal brain development, 
which is not complete until age 7 years. For 
these reasons, intensive therapy is contraindicated 
in patients under age 2 years, should be pre- 
scribed only with extreme caution in those age 
2-7, and possibly not begun until after age 13.'l 
Conclusion 
The DCCT and other trials of intensive therapy 
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Table 2.  Controlled Clinical Trials of the Effect of Glycemic Control on Chronic Complications in Type 2 Diabetes 
Study No. of Study Design/ Duration Glyca ted Glucose Concen- 
Population Pts Treatments (yrs) Retinopathy Nephropathy Hemoglobin tration (mg/dl) 
Outcomes 
Newly 1027 Diet, fixed- 6" 
diagnosed, not dose T, fixed- 
requiring insulin dose I, variable- 
dose I, fixed- 
dose P 
Insulin-treated, 110 IT, CT 6 
no or early 
microvascular 
complications, no 
hypertension 
Newly diagnosed 5102 Nonobese: 9 
CT = diet; 
IT = C, G, or 
I; obese CT = 
diet IT = C, 
G, I, or M 
NA NA NA 
Fewer in IT vs Fewer in IT vs Lower in IT vs 
CT developed CT developed CT, 7.1 * 1.1 
(7.7%, 32%) (7.7%, 28%) vs 9.4 i 1.5%' 
or progressed or progressed throughout 
(19.2%, 44%)b (11.5%, 32%)b study. 
at 6 yrs. at 6 yrs. 
NA NA Nonobese: lower 
in IT vs CT, 
6.7% vs 7.5%d; 
obese: lower in 
IT vs CT, 7% 
, vs 7.7%. 
Fasting and 1 hr 
after load higher in 
D and fixed I vs 
variable I through- 
out study. 
Fasting (126 i 36, 
164 * 50) and 
mean (157 * 34, 
221 * 45) lower in 
IT vs CTd through- 
out study. 
Nonobese: mean 
fasting lower in IT 
vs CT, 117 vs 
133.4d; obese! mean 
fasting lower in IT 
vs CT, 144 vs 
167.4.d ~~ 
T = tolbutamide; 1 = insulin; P = phenformin; M = metformin: D = diet alone; IT = intensive therapy; CT = conventional therapy; C = 
chlorpropamide; G = glyburide; NA = not applicable. 
"Tolbutamide and phenformin a m  stopped early. 
bp<0.05. 
cp<0.001. 
dp<oooo 1. 
indicated that achieving optimum blood glucose 
concentrations is a critical part of the treatment 
of diabetes mellitus. Barriers to widespread 
implementation of intensive therapy include 
unfamiliarity of health care providers and 
patients with it, and financial concerns. 
The DCCT used MDI or an insulin pump, self- 
monitoring of blood glucose at least 4 times/day 
with adjustment of insulin dosage based on the 
results, and careful attention to diet and exercise. 
Patient care was coordinated by teams of 
specialists. In contrast, most people with diabetes 
receive care from a primary care physician. Even 
lacking the support necessary to implement 
intensive care, however, improvement in glycemic 
control is indicated. Glycated hemoglobin 
concentrations in  the DCCT w.ere lower in  
patients receiving intensive therapy than in those 
receiving conventional therapy, but they were 
still not within normal limits. Thus, patients can 
be reassured that improvement in  glycemic 
control is beneficial despite failure to achieve 
normal values. 
The cost of treating the 1441 subjects in the 
DCCT for a mean of 6.5 years was $165 million, 
or over $17 thousand/patientjyear; some of this 
cost was probably dictated by research rather 
than clinical needs. It is difficult to assess what 
the cost would be if intensive therapy were 
implemented i n  all patients i n  whom i t  is 
indicated. Preliminary cost analysis is being 
conducted to determine if the possible savings 
from decreased complications will more than 
offset the cost of therapy. 
Intensive therapy should be pursued in all 
patients for whom it is indicated. This does not 
preclude treatments known to decrease the risk 
of complications, such as hypertension and 
hyperlipidemia, and to delay progression of 
diabetic nephropathy. In the future, treatment 
may also include agents to interfere with the 
harmful effects of hyperglycemia. 
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